Topical analgesic combinations for bortezomib neuropathy.
Prommer
Eric E
EE
D000287:Administration, Topical; D000316:Adrenergic alpha-Agonists / Q000008:administration & dosage / Q000627:therapeutic use; D000588:Amines / Q000008:administration & dosage / Q000627:therapeutic use; D000700:Analgesics / Q000008:administration & dosage / Q000627:therapeutic use*; D001897:Boronic Acids / Q000009:adverse effects* / Q000627:therapeutic use; D000069286:Bortezomib; D003000:Clonidine / Q000008:administration & dosage / Q000627:therapeutic use; D003509:Cyclohexanecarboxylic Acids / Q000008:administration & dosage / Q000627:therapeutic use; D004338:Drug Combinations; D018691:Excitatory Amino Acid Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D000077206:Gabapentin; D005782:Gels; D006801:Humans; D007649:Ketamine / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010147:Pain Measurement; D010265:Paraproteinemias / Q000150:complications; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000188:drug therapy*; D011480:Protease Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011719:Pyrazines / Q000009:adverse effects* / Q000627:therapeutic use; D016138:Walking; D005680:gamma-Aminobutyric Acid / Q000008:administration & dosage / Q000627:therapeutic use
D000316:Adrenergic alpha-Agonists; D000588:Amines; D000700:Analgesics; D001897:Boronic Acids; D003509:Cyclohexanecarboxylic Acids; D004338:Drug Combinations; D018691:Excitatory Amino Acid Antagonists; D005782:Gels; D011480:Protease Inhibitors; D011719:Pyrazines; D005680:gamma-Aminobutyric Acid; D007649:Ketamine; D000069286:Bortezomib; D000077206:Gabapentin; D003000:Clonidine